


REMARKS

Claim 30 is amended to be dependent on claim 34, rather than canceled claim 17. New claims 40-43 are directed to further aspects of applicants' invention and are supported throughout applicants' disclosure. See, e.g., the disclosure at page 3, lines 10-18, page 6, lines 3-8, and the Examples.

Respectfully submitted,



Brion P. Heaney (Reg. No. 32,542)
Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Boulevard, Suite 1400
Arlington, Virginia 22201
Direct Dial: (703) 812-5308
Facsimile: (703) 243-6410
Internet Address: heaney@mwzb.com

Filed: May 14, 2000

BPH:imm\K:\Sch\1655\Prelim Amendment.wpd

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Please amend claim 30 as follows:

30. A method according to claim 34 ~~17~~, wherein said LHRH analogue is administered in the amount of 2 µg-20 mg per kilogram of body weight and said anti-estrogen is administered in an amount of 0.1 µg-10 mg per kilogram of body weight.

Please add claims 40-42 as follows:

40. A method according to claim 34, wherein said LHRH analogue is Leuporelin, Cetrorelix, Antide, Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Lys(Mor)-Pro-D-Ala-NH₂, Ramorelix, or Zoladex.

41. A method according to claim 40, wherein anti-estrogen is Raloxifen, Droloxifen, or Centchroman.

42. A method according to claim 41, wherein said LHRH analogue is Antide and said anti-estrogen is Raloxifen.

43. A method according to claim 41, wherein said LHRH analogue is Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Lys(Mor)-Pro-D-Ala-NH₂ and said anti-estrogen is Droloxifen.